SCHEMBL13069320

SCHEMBL13069320

CCCc1ccnc2[nH]ccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 3/20 0.50
AXL P30530 1/20 0.50
NUDT1 P36639 5/20 0.48
CCNK O75909 2/20 0.47
CDK12 Q9NYV4 2/20 0.47
AURKB Q96GD4 3/20 0.45
JAK2 O60674 2/20 0.45
JAK3 P52333 2/20 0.45
ROCK1 Q13464 2/20 0.45
IKBKB O14920 2/20 0.45
CHUK O15111 2/20 0.45
DAPK3 O43293 1/20 0.45
PRKD3 O94806 1/20 0.45
MAP4K4 O95819 1/20 0.45
PAK4 O96013 1/20 0.45
CSF1R P07333 1/20 0.45
RET P07949 1/20 0.45
IGF1R P08069 1/20 0.45
FGFR1 P11362 1/20 0.45
PRKACA P17612 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19648515 0.90 PRKCI (0.47) PRKCIAXLNUDT1CCNKCDK12
SCHEMBL239630 0.85 NUDT1 (0.54) PRKCIAXLNUDT1CCNKCDK12
SCHEMBL14416607 0.79 PRKCI (0.50) PRKCIAXLNUDT1CCNKCDK12
SCHEMBL1752655 0.78 PRKCI (0.53) PRKCIAXLNUDT1CCNKCDK12
SCHEMBL14534111 0.78 PRKCI (0.53) PRKCIAXLNUDT1CCNKCDK12
SCHEMBL28311692 0.78 PRKCI (0.53) PRKCIAXLNUDT1CCNKCDK12
SCHEMBL1748621 0.78 PRKCI (0.53) PRKCIAXLNUDT1CCNKCDK12
SCHEMBL3088057 0.78 PRKCI (0.58) PRKCIAXLNUDT1CCNKCDK12
SCHEMBL2602399 0.78 PRKCI (0.53) PRKCIAXLNUDT1CCNKCDK12
SCHEMBL23563266 0.77 PRKCI (0.49) PRKCIAXLNUDT1CCNKCDK12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286390-A1 PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS NISSAN CHEMICAL INDUSTRIES LIMITED 2010-11-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286390-A1 PYRIDAZINONE COMPOUNDS AND P2X7 RECEPTOR INHIBITORS P2RY1, P2RX7, P2RX1 PRKCI 3815/4885AXL 1129/4885NUDT1 1138/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.